Literature DB >> 26353983

IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.

L Vuitton1, P Marteau2, W J Sandborn3, B G Levesque3, B Feagan4, S Vermeire5, S Danese6, G D'Haens7, M Lowenberg7, R Khanna4, G Fiorino6, S Travis8, J Y Mary9, L Peyrin-Biroulet10.   

Abstract

BACKGROUND: Crohn's disease (CD) is a chronic disabling and progressive IBD. Only strategies looking beyond symptoms and based on tight monitoring of objective signs of inflammation such as mucosal lesions may have the potential for disease modification. Endoscopic evaluation is currently the gold standard to assess mucosal lesions and has become a major therapeutic endpoint in clinical trials. Several endoscopic indices have been proposed to evaluate disease activity; unvalidated and arbitrary definitions have been used in clinical trials for defining endoscopic response and endoscopic remission in CD.
METHODS: In these recommendations from the International Organization for the Study of Inflammatory Bowel Disease, we first reviewed all technical aspects of available endoscopic scoring systems in the literature. Second, in order to achieve consensus on endoscopic definitions of remission and response in trials, a two-round vote based on a Delphi method was performed among 14 specialists in the field of IBDs.
RESULTS: At the end of the voting process, the investigators ranked first a >50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) or Crohn's Disease Endoscopic Index of Severity for the definition of endoscopic response, and an SES-CD 0-2 for the definition of endoscopic remission in CD. All experts agreed on a Rutgeerts' score i0-i1 for the definition of endoscopic remission after surgery. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  CROHN'S DISEASE

Mesh:

Year:  2015        PMID: 26353983     DOI: 10.1136/gutjnl-2015-309903

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

Review 1.  Evolving therapeutic goals in Crohn's disease management.

Authors:  Thomas Chateau; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2019-11-04       Impact factor: 4.623

2.  Editorial: Endoscopic Scoring Systems in Crohn's Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment?

Authors:  Anna M Buchner; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2017-10       Impact factor: 10.864

Review 3.  Mucosal healing in inflammatory bowel disease: Expanding horizon.

Authors:  Jimil Shah; Manik Lal Thakur; Usha Dutta
Journal:  Indian J Gastroenterol       Date:  2019-04-29

4.  Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence.

Authors:  Robert P Hirten; Ryan C Ungaro; Daniel Castaneda; Sarah Lopatin; Bruce E Sands; Jean Frederic Colombel; Benjamin L Cohen
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

5.  Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.

Authors:  Piotr Eder; Kamila Stawczyk-Eder; Katarzyna Korybalska; Natasza Czepulis; Joanna Luczak; Liliana Lykowska-Szuber; Iwona Krela-Kazmierczak; Krzysztof Linke; Janusz Witowski
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

6.  Predicting Risk of Postoperative Disease Recurrence in Crohn's Disease: Patients With Indolent Crohn's Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery.

Authors:  Kelly C Cushing; Richard Mclean; Keely G McDonald; Jenny K Gustafsson; Kathryn A Knoop; Devesha H Kulkarni; R Balfour Sartor; Rodney D Newberry
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

7.  Editorial: biologics in inflammatory bowel disease-time for direct comparisons.

Authors:  R C Ungaro; J-F Colombel
Journal:  Aliment Pharmacol Ther       Date:  2017-07       Impact factor: 8.171

Review 8.  Head-to-head trials in inflammatory bowel disease: past, present and future.

Authors:  Lieven Pouillon; Simon Travis; Peter Bossuyt; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-17       Impact factor: 46.802

Review 9.  Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials.

Authors:  Parakkal Deepak; Joel G Fletcher; Jeff L Fidler; David H Bruining
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

10.  Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan.

Authors:  Kouhei Fukushima; Akira Sugita; Kitaro Futami; Ken-Ichi Takahashi; Satoshi Motoya; Hideaki Kimura; Shusaku Yoshikawa; Yoshitaka Kinouchi; Hideki Iijima; Katsuya Endo; Toshihumi Hibi; Mamoru Watanabe; Iwao Sasaki; Yasuo Suzuki
Journal:  Surg Today       Date:  2018-01-30       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.